Close Menu

NEW YORK (GenomeWeb) – Qiagen said after the close of the market on Wednesday that Laboratory Corporation of America has joined its "Day-One" lab readiness program designed to expedite patient access to Qiagen companion diagnostic products following regulatory approval of the tests and associated drugs.

Qiagen's Day-One program is intended to enable molecular diagnostic labs to begin preparing for commercial launch of new drugs and in vitro diagnostic tests being developed by Qiagen and its partners once US Food and Drug Administration approval is obtained.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A German shepherd called Nala has had her genome sequenced.

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.